These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22541745)

  • 1. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.
    de la Motte S; Beier J; Schmid K; Pascual S; Jansat JM; Gil EG
    Int J Clin Pharmacol Ther; 2012 Jun; 50(6):403-12. PubMed ID: 22541745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
    Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M
    J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
    Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
    Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
    Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E
    Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.
    Ortiz S; Flach S; Caracta C; Gil EG; Jansat JM
    J Clin Pharmacol; 2012 Jun; 52(6):819-27. PubMed ID: 21628603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
    COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.
    Gelb AF; Tashkin DP; Make BJ; Zhong X; Garcia Gil E; Caracta C;
    Respir Med; 2013 Dec; 107(12):1957-65. PubMed ID: 23916502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants.
    Li W; Daoud SZ; Trivedi R; Lukka PB; Jimenez E; Molins E; Stewart C; Bharali P; Garcia-Gil E
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2725-2735. PubMed ID: 38046981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
    Maltais F; Milot J
    Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.
    Jones P
    Adv Ther; 2013 Apr; 30(4):354-68. PubMed ID: 23553509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile.
    Gavaldà A; Gras J; Llupià J; Aubets J; Beleta J; Llenas J
    Life Sci; 2012 Feb; 90(7-8):301-5. PubMed ID: 22213116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
    Jones PW; Singh D; Bateman ED; Agusti A; Lamarca R; de Miquel G; Segarra R; Caracta C; Garcia Gil E
    Eur Respir J; 2012 Oct; 40(4):830-6. PubMed ID: 22441743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.
    Schmid K; Pascual S; Gil EG; Ortiz S; Jansat JM
    Clin Ther; 2010 Sep; 32(10):1798-812. PubMed ID: 21194604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.
    Jansat JM; Lamarca R; Garcia Gil E; Ferrer P
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):460-8. PubMed ID: 19640353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD.
    Marth K; Schuller E; Pohl W
    Respir Med; 2015 May; 109(5):616-24. PubMed ID: 25796962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the efficacy and safety of aclidinium bromide in patients with COPD.
    Alagha K; Bourdin A; Tummino C; Chanez P
    Ther Adv Respir Dis; 2011 Feb; 5(1):19-28. PubMed ID: 20884687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.
    Ortiz S; Flach S; Ho J; Li F; Caracta CF; Gil EG; Jansat JM
    Biopharm Drug Dispos; 2012 Jan; 33(1):39-45. PubMed ID: 22275272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Page CP; Matera MG
    Expert Opin Pharmacother; 2013 Jun; 14(9):1205-14. PubMed ID: 23566013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
    COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
    Rennard SI; Scanlon PD; Ferguson GT; Rekeda L; Maurer BT; Garcia Gil E; Caracta CF
    Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.